Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG7XHE)

Drug Name

Monalizumab Drug Info

Synonyms

IPH2201

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[1]
Head and neck cancer	2D42	Phase 1/2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting NKG2-A/B-activating NK receptor (NKG2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NN8765	DMCFPBE	Rheumatoid arthritis	FA20	Phase 2	[4]
BMS-986315	DMTEY1L	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
IM1240	DMTV0DK	Aggressive cancer	2A00-2F9Z	Preclinical	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
NKG2-A/B-activating NK receptor (NKG2A)	TTC4IMS	NKG2A_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02643550) Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Handbook of Therapeutic Antibodies. 2014. 1. Page(1098).
5	ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
6	Clinical pipeline report, company report or official report of Purple